TY - JOUR
T1 - Variability in Antibiotic Use Across PICUs
AU - Brogan, Thomas V.
AU - Thurm, Cary
AU - Hersh, Adam L.
AU - Gerber, Jeffrey S.
AU - Smith, Michael J.
AU - Shah, Samir S.
AU - Courter, Joshua D.
AU - Patel, Sameer J.
AU - Parker, Sarah K.
AU - Kronman, Matthew P.
AU - Lee, Brian R.
AU - Newland, Jason G.
N1 - Funding Information:
1Division of Pediatric Critical Care Medicine, Department of Pediatrics, Seattle Children’s Hospital, University of Washington School of Medi-cine, Seattle, WA. 2Children’s Hospital Association, Lenexa, KS. 3Division of Pediatric Infectious Diseases, Department of Pediatrics, Uni-versity of Utah, Salt Lake City, UT. 4Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, PA. 5Division of Pediatric Infectious Diseases, University of Louisville School of Medicine, Louisville, KY. 6Divisions of Hospital Medicine and Infectious Diseases, Cincinnati Chil-dren’s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH. 7Divisions of Hospital Medicine, Cincinnati Children’s Hospital Medical Cen-ter and the University of Cincinnati College of Medicine, Cincinnati, OH. 8Division of Infectious Diseases, Ann & Robert H. Lurie Children’s Hos-pital, Chicago, IL. 9Departments of Pediatrics and Infection Control, Division of Infectious Diseases, University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO. 10Division of Infectious Diseases, Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA. 11Division of Infectious Diseases, Children’s Mercy Hospital-Kansas City, Kansas City, MO. 12Division of Infectious Diseases, Washington University School of Medi-cine, St. Louis, MO. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/pccmjournal). Dr. Hersh’s institution received funding from the Agency for Healthcare Research and Quality and Merck. Dr. Lee’s institution received funding from the Patient-Centered Outcomes Research Institute and Pfizer. Dr. Newland’s institution received funding from Pfizer for antimicrobial stewardship. The remaining authors have disclosed that they do not have any potential conflicts of interest. For information regarding this article, E-mail: [email protected] Copyright © 2018 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies DOI: 10.1097/PCC.0000000000001535
Publisher Copyright:
© 2018 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Objectives: To characterize and compare antibiotic prescribing across PICUs to evaluate the degree of variability. Design: Retrospective analysis from 2010 through 2014 of the Pediatric Health Information System. Setting: Forty-one freestanding children's hospital. Subjects: Children aged 30 days to 18 years admitted to a PICU in children's hospitals contributing data to Pediatric Health Information System. Interventions: To normalize for potential differences in disease severity and case mix across centers, a subanalysis was performed of children admitted with one of the 20 All Patient Refined-Diagnosis Related Groups and the seven All Patient Refined-Diagnosis Related Groups shared by all PICUs with the highest antibiotic use. Results: The study included 3,101,201 hospital discharges from 41 institutions with 386,914 PICU patients. All antibiotic use declined during the study period. The median-adjusted antibiotic use among PICU patients was 1,043 days of therapy/1,000 patient-days (interquartile range, 977-1,147 days of therapy/1,000 patient-days) compared with 893 among non-ICU children (interquartile range, 805-968 days of therapy/1,000 patient-days). For PICU patients, the median adjusted use of broad-spectrum antibiotics was 176 days of therapy/1,000 patient-days (interquartile range, 152-217 days of therapy/1,000 patient-days) and was 302 days of therapy/1,000 patient-days (interquartile range, 220-351 days of therapy/1,000 patient-days) for antimethicillin-resistant Staphylococcus aureus agents, compared with 153 days of therapy/1,000 patient-days (interquartile range, 130-182 days of therapy/1,000 patient-days) and 244 days of therapy/1,000 patient-days (interquartile range, 203-270 days of therapy/1,000 patient-days) for non-ICU children. After adjusting for potential confounders, significant institutional variability existed in antibiotic use in PICU patients, in the 20 All Patient Refined-Diagnosis Related Groups with the highest antibiotic usage and in the seven All Patient Refined-Diagnosis Related Groups shared by all 41 PICUs. Conclusions: The wide variation in antibiotic use observed across children's hospital PICUs suggests inappropriate antibiotic use.
AB - Objectives: To characterize and compare antibiotic prescribing across PICUs to evaluate the degree of variability. Design: Retrospective analysis from 2010 through 2014 of the Pediatric Health Information System. Setting: Forty-one freestanding children's hospital. Subjects: Children aged 30 days to 18 years admitted to a PICU in children's hospitals contributing data to Pediatric Health Information System. Interventions: To normalize for potential differences in disease severity and case mix across centers, a subanalysis was performed of children admitted with one of the 20 All Patient Refined-Diagnosis Related Groups and the seven All Patient Refined-Diagnosis Related Groups shared by all PICUs with the highest antibiotic use. Results: The study included 3,101,201 hospital discharges from 41 institutions with 386,914 PICU patients. All antibiotic use declined during the study period. The median-adjusted antibiotic use among PICU patients was 1,043 days of therapy/1,000 patient-days (interquartile range, 977-1,147 days of therapy/1,000 patient-days) compared with 893 among non-ICU children (interquartile range, 805-968 days of therapy/1,000 patient-days). For PICU patients, the median adjusted use of broad-spectrum antibiotics was 176 days of therapy/1,000 patient-days (interquartile range, 152-217 days of therapy/1,000 patient-days) and was 302 days of therapy/1,000 patient-days (interquartile range, 220-351 days of therapy/1,000 patient-days) for antimethicillin-resistant Staphylococcus aureus agents, compared with 153 days of therapy/1,000 patient-days (interquartile range, 130-182 days of therapy/1,000 patient-days) and 244 days of therapy/1,000 patient-days (interquartile range, 203-270 days of therapy/1,000 patient-days) for non-ICU children. After adjusting for potential confounders, significant institutional variability existed in antibiotic use in PICU patients, in the 20 All Patient Refined-Diagnosis Related Groups with the highest antibiotic usage and in the seven All Patient Refined-Diagnosis Related Groups shared by all 41 PICUs. Conclusions: The wide variation in antibiotic use observed across children's hospital PICUs suggests inappropriate antibiotic use.
KW - antimicrobial stewardship
KW - children's hospitals
KW - complex chronic conditions
KW - critical care
KW - pediatric intensive care units
KW - transplantation
UR - http://www.scopus.com/inward/record.url?scp=85053888105&partnerID=8YFLogxK
U2 - 10.1097/PCC.0000000000001535
DO - 10.1097/PCC.0000000000001535
M3 - Article
C2 - 29533352
AN - SCOPUS:85053888105
SN - 1529-7535
VL - 19
SP - 519
EP - 527
JO - Pediatric Critical Care Medicine
JF - Pediatric Critical Care Medicine
IS - 6
ER -